AtriCure (NASDAQ:ATRC) Upgraded by UBS Group to Strong-Buy Rating

UBS Group upgraded shares of AtriCure (NASDAQ:ATRC) to a strong-buy rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other analysts have also recently issued reports on the company. Zacks Research raised AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Weiss Ratings upgraded AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Wall Street Zen cut AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Freedom Capital upgraded AtriCure to a “strong-buy” rating in a report on Wednesday, April 1st. Three research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $48.50.

AtriCure Trading Up 2.9%

Shares of ATRC opened at $40.89 on Tuesday. The stock has a market capitalization of $2.08 billion, a P/E ratio of 194.72 and a beta of 1.24. The company has a quick ratio of 3.18, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The firm has a fifty day simple moving average of $30.68 and a two-hundred day simple moving average of $31.30. AtriCure has a twelve month low of $25.36 and a twelve month high of $43.18.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same quarter last year, the firm earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, research analysts anticipate that AtriCure will post 0.2 EPS for the current year.

Insider Transactions at AtriCure

In related news, Director Karen Prange sold 3,000 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total value of $85,950.00. Following the completion of the transaction, the director directly owned 26,373 shares of the company’s stock, valued at $755,586.45. This represents a 10.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. bought a new position in shares of AtriCure in the 2nd quarter worth approximately $37,000. Harbor Investment Advisory LLC bought a new stake in shares of AtriCure during the second quarter valued at approximately $40,000. Smartleaf Asset Management LLC grew its stake in AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the period. Fifth Third Bancorp purchased a new stake in AtriCure in the first quarter worth $51,000. Finally, Global Retirement Partners LLC bought a new position in AtriCure in the fourth quarter worth $73,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.